55. The solid form of claim 1, having an X-ray powder diffraction pattern comprising peaks at about 7.2, 9.1, 14.5, 15.7, 16.8, 18.3, 21.9, 22.7, 29.9 and 36.9 degrees 2θ.

56. The solid form of any one of claims 53-55, having a differential scanning calorimetry plot comprising an endothermic event with an onset temperature of about 267 °C.

57. The solid form of any one of claims 53-56, which is hydrated.

58. A mixture comprising two or more solid forms selected from the solid forms of claims 1-58.

59. A pharmaceutical composition comprising the solid form of any one of claims 1-58 and a pharmaceutical acceptable carrier, diluent or excipient.

60. The pharmaceutical composition of claim 59, wherein the composition is formulated for oral, parenteral, or intravenous administration.

61. The pharmaceutical composition of claim 59 or 60, wherein the composition is formulated as a single unit dosage form.

62. The pharmaceutical composition of claim 61, wherein the oral dosage form is a tablet or capsule.

63. Use of a solid form of any one of claims 1 to 62 in the manufacture of a medicament for treating a disease or disorder. ~~A method of treating, managing or preventing a disease or disorder comprising administering to a patient a solid form of any of claims 1-62,~~ wherein the disease or disorder is selected from the group consisting of cancer, a disorder associated with angiogenesis, pain, macular degeneration or a related syndrome, a skin disease, a pulmonary disorder, an asbestos-related disorder, a parasitic disease, an immunodeficiency disorder, a CNS disorder, CNS injury, atherosclerosis or a related disorder, dysfunctional sleep or a related disorder, hemoglobinopathy or a related disorder~~, or~~ and a TNFα related disorder.

64. The use ~~method~~ of claim 63, further comprising administering a second active agent.